My ePortfolio Register   

Expert insight: Metastatic hormone sensitive prostate cancer latest

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.02.18
Views: 1232

Professor Karim Fizazi and Professor Nicholas James

Professor Karim Fizazi and Professor Nicholas James discuss data presented at the 2018 Genitourinary Cancers Symposium as well as the current landscape and the future for the treatment and management of patients with metastatic hormone sensitive prostate cancer (mHSPC)

They discuss what guides treatment choices for these patients and the factors that influence this decision including patient choice, toxicitiy and the efficacy data for abiraterone and docetaxel.

The discussion looks to the future for patients with mHSPC with conversations around the STAMPEDE and PEACE1 trials.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence